AR033830A1 - Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas - Google Patents

Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas

Info

Publication number
AR033830A1
AR033830A1 ARP010103395A ARP010103395A AR033830A1 AR 033830 A1 AR033830 A1 AR 033830A1 AR P010103395 A ARP010103395 A AR P010103395A AR P010103395 A ARP010103395 A AR P010103395A AR 033830 A1 AR033830 A1 AR 033830A1
Authority
AR
Argentina
Prior art keywords
antagonist
manufacture
viric
antagonists
infections
Prior art date
Application number
ARP010103395A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR033830A1 publication Critical patent/AR033830A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de una cantidad efectiva de un antagonista de los receptores de la IL-8 para la manufactura de un medicamento para tratar la sintomatología del resfriado común causado por infección de rinovirus humano, otros enterovirus, herpesvirus, coronavirus, influenzavirus, parainfluenzavirus, virus respiratorio sincitial o adenovirus en un humano que lo necesite. Uso del antagonista mencionado en conjunción con un antihistamínico, un anti inflamatorio. Uso del antagonista en done se administra oralmente o por inhalación. Uso del antagonista para la manufactura de un medicamento para tratar el asma, bronquitis crónica, enfermedad pulmonar obstructiva crónica, otitis media, sinucitis y neumonía.
ARP010103395A 2000-07-18 2001-07-16 Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas AR033830A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21905300P 2000-07-18 2000-07-18

Publications (1)

Publication Number Publication Date
AR033830A1 true AR033830A1 (es) 2004-01-07

Family

ID=22817645

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103395A AR033830A1 (es) 2000-07-18 2001-07-16 Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas

Country Status (17)

Country Link
EP (1) EP1307190A4 (es)
JP (1) JP2004509852A (es)
KR (1) KR20030019587A (es)
CN (1) CN1449285A (es)
AR (1) AR033830A1 (es)
AU (1) AU2001273497A1 (es)
BR (1) BR0112603A (es)
CA (1) CA2418162A1 (es)
CZ (1) CZ2003132A3 (es)
HU (1) HUP0300754A3 (es)
IL (1) IL153921A0 (es)
MX (1) MXPA03000500A (es)
NO (1) NO20030201L (es)
NZ (1) NZ523659A (es)
PL (1) PL365886A1 (es)
WO (1) WO2002005814A1 (es)
ZA (1) ZA200300474B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001561A (es) * 2004-08-04 2007-04-16 Schering Corp Formulacion farmaceutica que comprende pleconaril para tratamiento de enfermedades de vias aereas.
US20170100385A1 (en) * 2014-05-12 2017-04-13 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions comprising danirixin for treating infectious diseases
EP3884932A1 (en) * 2020-03-26 2021-09-29 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19
IL296751A (en) * 2020-03-26 2022-11-01 Dompe Farm Spa cxcl8 inhibitors for use in the treatment of covid-19
EP4008325A1 (en) * 2020-12-02 2022-06-08 Dompe' Farmaceutici S.P.A. Cxcl8 inhibitors for use in the treatment of covid-19

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
WO1996005836A2 (en) * 1994-08-25 1996-02-29 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
SE9802729D0 (sv) * 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
SE9802937D0 (sv) * 1998-09-01 1998-09-01 Astra Pharma Prod Novel compounds

Also Published As

Publication number Publication date
NZ523659A (en) 2006-01-27
AU2001273497A1 (en) 2002-01-30
ZA200300474B (en) 2004-08-17
CZ2003132A3 (cs) 2003-09-17
HUP0300754A3 (en) 2009-03-02
HUP0300754A2 (hu) 2003-08-28
EP1307190A1 (en) 2003-05-07
EP1307190A4 (en) 2007-08-22
CN1449285A (zh) 2003-10-15
NO20030201L (no) 2003-03-17
MXPA03000500A (es) 2003-06-24
CA2418162A1 (en) 2002-01-24
NO20030201D0 (no) 2003-01-15
JP2004509852A (ja) 2004-04-02
IL153921A0 (en) 2003-07-31
WO2002005814A1 (en) 2002-01-24
PL365886A1 (en) 2005-01-10
BR0112603A (pt) 2004-08-24
KR20030019587A (ko) 2003-03-06

Similar Documents

Publication Publication Date Title
Ding et al. The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function
NO20073337L (no) Fremgangsmater for behandling av andedrettssykdommer ved anvendelse av antagonister av interleukin-1 reseptor type 1
CY1108978T1 (el) Συνδυασμος ενωσεων μεθυλξανθινης και στεροειδων για να θεραπευονται χρονιες αναπνευστικες ασθενειες
JP2023528810A (ja) レムデシビル治療方法
CR8918A (es) Derivados de triazolopiridinilsulfanilo como inhibidores de quinasa map p38
DK1326595T3 (da) Administration af resveratrol til at behandle inflammatoriske respiratoriske lidelser
AR062556A1 (es) Composiciones farmaceuticas de clonazepam y metodos de uso de las mismas
JP2012500091A5 (es)
BR0101456A (pt) Combinações de antagonistas do fator deliberação de corticotropina e secretagogos dohormÈnio de crescimento
NO20075287L (no) Kombinasjon av antikolinergika og leukotnen-reseptorantagonister for behandling av andedrettslidelser
KR20020032591A (ko) 라이노바이러스 감염에서의 ｃｓａｉｄ의 용도
Turner The common cold
Du et al. Lianhuaqingwen capsule inhibits influenza-induced bacterial adhesion to respiratory epithelial cells through down-regulation of cell adhesion molecules
AR033830A1 (es) Uso de los antagonistas de los receptores de la il-8 en el tratamiento de las infecciones viricas
UY30935A1 (es) Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones.
EA201170405A1 (ru) Монотерпены для лечения заболеваний дыхательных путей, в частности, бронхолегочных заболеваний
Bonville et al. Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis
Majdalawieh et al. Immunomodulatory and anti-inflammatory effects of berberine in lung tissue and its potential application in prophylaxis and treatment of COVID-19
AR030753A1 (es) Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
Liu et al. Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice
WO2008024543A3 (en) Method of using composition comprising pomegranate extracts against influenza
CN106309558A (zh) 一种鼻腔喷雾剂
CA3174328A1 (en) Furosemide compositions and uses thereof for supportive therapy in coronavirus infection
Garg et al. Tobacco: An invisible and immediate threat for COVID 19
UY27566A1 (es) Combinación farmacéutica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal